Browse Our Resources

The U.S. Food and Drug Administration (FDA) has approved three medications for use in treating opioid dependence: methadone, buprenorphine, and naltrexone. Extended release naltrexone, brand name Vivitrol®, is a… Read More

Under HAT, pharmacological heroin is administered under strict controls in a clinical setting to those who have failed in other treatments like methadone. Every published evaluation of HAT has shown extremely positive… Read More

Watch the recording now! Harm reduction services and syringe exchange are more than just a prevention strategy. Access to these vital services enables HIV testing, linkage to care and other critical health/social… Read More

On April 7, 2015, Ethan Nadelmann, Executive Director of the Drug Policy Alliance, presented oral testimony in support of sections 11-20 of SB275 at a hearing of the Nevada State Senate Revenue and Economic Development… Read More

This report reflects a new evolution in the thinking of the Global Commission, which includes Kofi Annan, Richard Branson, and the former presidents of Brazil, Chile, Colombia, Mexico, Poland, Portugal and Switzerland.… Read More

There is an extensive body of literature documenting the stigma associated with alcohol and other drug problems. No physical or psychiatric condition is more associated with social disapproval and discrimination than… Read More

The U.S. refuses to adopt an evidence-based HIV/AIDS prevention strategy, costing us hundreds of thousands of lives and hundreds of millions of dollars. However, in countries where addiction is treated as a health issue… Read More

The Affordable Care Act (ACA) represents a remarkable opportunity for criminal justice and drug policy reform advocates to advance efforts to enact policy changes that promote safe and healthy communities, without… Read More

The Global Commission, whose members include Kofi Annan and four former presidents, calls the drug war a failure and advocates a paradigm shift in global drug policy. The commission's bold… Read More

This volume includes a variety of perspectives on harm reduction approaches, together with an analysis of the concept's role within drug policies, both in Europe and beyond. Readers may not necessarily agree with… Read More